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Abstract
The human cathelicidin LL-37 is a cationic host defense peptide (antimicrobial peptide) expressed
primarily by neutrophils and epithelial cells. This peptide, up-regulated under conditions of
inflammation, has immunomodulatory and antimicrobial functions. We demonstrate that LL-37 is a
potent inhibitor of human neutrophil apoptosis, signaling through P2X7 receptors and G-protein-
coupled receptors other than the formyl peptide receptor-like-1 molecule. This process involved
modulation of Mcl-1 expression, inhibition of BID and procaspase-3 cleavage, and the activation of
phosphatidylinositol-3 kinase but not the extracellular signal-regulated kinase 1/2 mitogen-activated
protein kinase pathway. In contrast to the inhibition of neutrophil apoptosis, LL-37 induced apoptosis
in primary airway epithelial cells, demonstrating alternate consequences of LL-37-mediated
modulation of apoptotic pathways in different human primary cells. We propose that these novel
immunomodulatory properties of LL-37 contribute to peptide-mediated enhancement of innate host
defenses against acute infection and are of considerable significance in the development of such
peptides and their synthetic analogs as potential therapeutics for use against multiple antibiotic-
resistant infectious diseases.
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INTRODUCTION
Cationic host defense peptides (CHDP; also known as antimicrobial peptides) are key,
evolutionarily conserved components of host defenses [1]. The importance of CHDP to human
immunity is indicated by the increased susceptibility to infection of individuals with specific
granule deficiency [2] and morbus Kostmann patients [3] (conditions in which neutrophil
deficiency in defensins and cathelicidin, respectively, constitute key components of the
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disease) and by the up-regulation of peptide expression in lung [4], skin [5], and other sites in
response to inflammation. Furthermore, studies using knockout mouse models, transgenics,
and gene therapy augmentation clearly demonstrate the significance of CHDP to host defense
against infections [6-10].
Recently, various CHDP have been shown to have immunomodulatory properties [11], with
a growing number of these demonstrated in vivo, including chemokine production,
angiogenesis, anti-endotoxin activity, and chemotaxis [12-15]. In addition, multiple studies of
CHDP have demonstrated broad-spectrum antimicrobial activities in vitro. Consequently,
development of CHDP and their synthetic derivatives promises future antimicrobial
therapeutics relatively unaffected by common bacterial resistance mechanisms and potentially
combining microbicidal activities with immunomodulatory properties [16].
The CHDP demonstrating the most significant immunomodulatory potential to date is LL-37,
the predominant, mature peptide fragment of the sole human cathelicidin, human cationic
antimicrobial protein (hCAP)-18. This peptide is found in neutrophil-specific granules,
produced by a range of epithelial cells and to a lesser extent, by lymphocytes and macrophages
[17]. LL-37 expression has been detected at ∼5 μg/ml in bronchoalveolar lavage (BAL) from
healthy infants and is up-regulated by inflammation, detected in BAL from infants with
pulmonary infections and in individuals with cystic fibrosis lung disease at up to ∼30 μg/ml
and ∼15 μg/ml, respectively [4,18], and at levels of ∼1.5 mg/ml in psoriatic skin lesions [5].
The full extent of the immunomodulatory functions of LL-37 and the underlying mechanisms
involved remain undetermined and are of considerable significance in the development of
therapeutic, synthetic analogs. We hypothesized that the potential for LL-37 to modulate the
function and survival of key innate-immune effector cells could be critical to enhancing the
clearance of infection and resolution of inflammation. In particular, neutrophils, a cell type for
which LL-37 is directly and indirectly chemotactic [12,19-22], represent a key component of
innate defense against infection. These cells have a short half-life, “programmed” to die by
apoptosis, and exert a defensive role by intracellular killing and the release of defensins and
cathelicidins, lytic enzymes, proteases, and inflammatory mediators [23,24]. In this study, we
demonstrate that LL-37 acted as a potent inhibitor of human neutrophil apoptosis, signaling
through P2X7 receptors and G-protein-coupled receptors other than formyl peptide receptor-
like-1 molecule (FPRL-1) and modulating Mcl-1 expression, inhibiting cleavage of BID and
procaspase-3, and involving the activation of phosphatidylinositol-3 kinase (PI-3K, but not the
extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK)
pathway. In contrast, LL-37 induced apoptosis in primary airway epithelial cells,
demonstrating alternate consequences of LL-37-mediated modulation of apoptotic pathways
in different human primary innate-immune effector cells exposed to this CHDP.
MATERIALS AND METHODS
Reagents
Recombinant human tumor necrosis factor α (TNF-α), interleukin (IL)-1β, and granulocyte
macrophage-colony stimulating factor (GM-CSF) were purchased from Research Diagnostics
Inc. (Flanders, NJ). H-Trp-Arg-Trp-Trp-Trp-Trp-CONH2 (WRW4) and H-Trp-Lys-Tyr-Met-
Val-D-Met-CONH2 (WKYMVm; both reconstituted in dimethyl sulfoxide, according to the
manufacturer's instructions), caspase inhibitor I [Z-Val-Ala-Asp-fluoromethylketone (Z-
VAD-FMK)], and pertussis toxin (PTX) were purchased from Calbiochem, Merk Biosciences
(Nottingham, UK). Oxidized adenosine 5′-triphosphate (ATP), PD098059, and wortmannin
were purchased from Sigma-Aldrich (Poole, UK, or Oakville, Ontario, Canada). Rabbit
polyclonal antibodies against Mcl-1, BID, and cleaved caspase-3 were purchased from Cell
Signaling Technology (Mississauga, Ontario, Canada). Mouse polyclonal antibody against
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caspase-3 was purchased from Alexis Biochemicals (Axxora, San Diego, CA). Horseradish
peroxidase (HRP)-conjugated goat antirabbit and antimouse immunoglobulin G antibodies
were purchased from Cell Signaling Technology (Beverly, MA) and Amersham Biosciences
(Piscataway, NJ), respectively. Lipopolysaccharide (LPS) from Pseudomonas aeruginosa
Strain H103 was highly purified free of proteins and lipids using the Darveau-Hancock method
as described previously [25]. Briefly, P. aeruginosa was grown overnight in Luria-Bertani
broth at 37°C. Cells were collected and washed, and the isolated LPS pellets were extracted
with a 2:1 chloroform:methanol solution to remove contaminating lipids. Purified LPS samples
were quantitated using an assay for the specific sugar 2-keto-3-deoxyoctosonic acid assay and
then resuspended in endotoxin-free water (Sigma-Aldrich). LL-37 was synthesized by N-(9-
fluorenyl) methoxycarbonyl chemistry at the Nucleic Acid/Protein Service unit at the
University of British Columbia (UBC; Vancouver, Canada), as described previously [26].
Peptides were purified by reverse-phase high-performance liquid chromatography and were at
least 98% pure. LL-37 was dissolved in endotoxin-free water (Sigma-Aldrich) and stored at
−20°C until further use. The concentration of the peptides in solution was determined by amino
acid analysis. All reagents were tested to ensure that they were free of endotoxin and
reconstituted in endotoxin-free water.
Isolation of human blood neutrophils
Fresh human venous blood was collected from volunteers, according to University of
Edinburgh (Scotland) Research Ethics Committee approval #1702/95/4/72 or UBC Clinical
Research Ethics Board protocol C02-0091, using sodium citrate solution (Phoenix Pharma
Ltd., Gloucester, UK) as an anticoagulant or Vacutainer® collection tubes containing sodium
heparin (BD Biosciences, Mississauga, Ontario, Canada, or Oxford, UK).
For neutrophil isolation, blood was centrifuged at 300 g for 20 min at room temperature,
platelet-rich plasma was removed, and cells were suspended gently in 1% Dextran T-500
(Amersham Pharmacia Biotech, Buckingham, UK) in 0.9% saline and sedimented for 30 min
at room temperature. The leukocyte-rich upper layer was then fractionated by using three-step
discontinuous, isotonic Percoll gradients as described previously [27]. Briefly, cells were
centrifuged at 300 g for 6 min, resuspended in 55% isotonic Percoll (Amersham Pharmacia
Biotech), layered on top of 68% and 81% isotonic Percoll layers, and centrifuged at 700 g for
20 min at room temperature. Neutrophils were collected, washed in phosphate-buffered saline
(PBS) without calcium or magnesium, and resuspended in Iscoves's Dulbecco's modified
Eagle's medium (IDMEM; Invitrogen, Paisley, UK, or Burlington, Ontario, Canada) with 10%
(v/v) heat-inactivated fetal bovine serum (FBS). Alternatively, neutrophils were purified by
Ficoll-Paque gradient centrifugation as described previously [28]. Briefly, cells were
centrifuged at 200 g for 7 min, remaining erythrocytes were lysed hypotonically with ice-cold,
distilled water for 30 s, followed by restoration of tonicity with 2.5% saline, and neutrophils
were separated by centrifugation over a Ficoll-Paque Plus (Amersham Pharmacia Biotech)
density gradient at 400 g for 25 min at 4°C. The cells were washed with Krebs-Ringer phosphate
buffer (pH 7.3), containing glucose (10 mM) and Mg2+ (1.5 mM), and resuspended in
RPMI-1640 media (Invitrogen), supplemented with 10% (v/v) heat-inactivated FBS, 1% (v/v)
L-glutamine, and 1 nM sodium pyruvate. Polymorphonuclear leukocytes isolated were 95–
98% neutrophils using morphological criteria, and viability was assessed by trypan blue
exclusion. Dose-dependent LL-37-mediated inhibition of neutrophil apoptosis was observed
by fluorescent-activated cell sorter (FACS), irrespective of the anticoagulant or methodology
used to isolate cells. The former method was used in receptor inhibitor studies and the latter
method, in analyses by Western immunoblot and enzyme-linked immunosorbent assay
(ELISA).
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Neutrophil apoptosis
Freshly isolated human blood neutrophils were incubated at 37°C, 5% CO2, for 0, 1, 4, or 20
h, at 6 × 105 cells in 200 μl IDMEM with 10% (v/v) heat-inactivated FBS in flexible, 96-well
culture plates in the presence of LL-37, GM-CSF, or WKYMVm at the stated concentrations
or a vehicle control, at least in duplicate. Where inhibitors were used, these (or vehicle control)
were added 30 min before the addition of LL-37. Apoptosis was assessed by flow cytometry
using fluorescein isothiocyanate (FITC)-labeled Annexin V (Roche Applied Sciences, Lewes,
East Sussex, UK), diluted 1:500 with binding buffer (Hanks' balanced salt solution with 5 mM
CaCl) and 5 μg/ml propidium iodide (Molecular Probes/Invitrogen) at 4°C. The samples were
analyzed using a FACSCalibur system (BD Biosciences), counting a minimum of 10,000 cells.
In addition to FACS analyses, apoptosis was assessed using standard morphological analysis
of distinctive apoptotic morphology. Samples (100 μl) of cells were cytocentrifuged, fixed in
methanol, stained with Reastain Quick-Diff (Reagena, Garridor, UK), and examined using oil
immersion microscopy. Total cell counts were performed in duplicate by haemocytometer and
light microscopy (using standard methodology) for each well upon removal of gently
resuspended cells for FACS analysis and cytospin.
Western immunoblotting
Fresh human blood neutrophils (7.5×106), per condition, in 5 ml RPMI-1640 media
[supplemented with 10% (v/v) heat-inactivated FBS, 1% (v/v) L-glutamine, and 1 nM sodium
pyruvate] were exposed to LL-37 at the concentrations detailed or endotoxin-free water as a
vehicle control and incubated at 37°C, 5% CO2, for 4 h. Cells were washed with ice-cold PBS
containing 1 mM sodium orthovanadate (Sigma-Aldrich) and lysed with 150 μl 1% Triton
X-100, 10 mM Tris, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride
buffer containing Sigma protease inhibitor cocktail [104 mM 4-(2-aminoethyl)
benzenesulfonyl fluoride, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM
pepstatin A, 1.4 mM E-64] and phosphatase inhibitor cocktail 2 (sodium orthovanadate, sodium
molybdate, sodium tartrate, imidazole). The protein concentrations of lysates were determined
using a bicinchoninic acid assay (Pierce, Rockford, IL, or Cramlington, UK). Equivalent lysate
(15–40 μg) was resolved on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA), which
were blocked for 1 h with 20 mM Tris, pH 7.4, 150 mM NaCl, and 0.1% Tween 20 (TBST)
containing 5% skimmed milk powder (TBST/milk). Subsequently, the nitrocellulose
membranes were incubated with anti-Mcl-1, anti-BID, anticaspase-3, or anti-cleaved caspase-3
antibodies at 1/1000 dilution in TBST/milk for 1 h at room temperature. Membranes were
washed for 30 min in TBST and then incubated with a 1/5000 dilution of HRP-conjugated goat
antimouse or antirabbit antibody (in TBST/milk) for 1 h. The membranes were washed for 30
min in TBST and developed with chemiluminescence peroxidase substrate (Sigma-Aldrich),
according to the manufacturer's instructions. To quantify bands, the luminescence was detected
with Versadoc (Bio-Rad). The blots were stripped using Restore™ Western blot stripping
buffer (Pierce), according to the manufacturer's instructions, and reprobed with an anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody, and densitometry was
performed to allow correction for protein loading.
Chemotaxis assay
Transwell® polyester-permeable supports (pore size 3.0 μm, diameter 6.5 mm; Corning Life
Sciences, UK) were used for chemotaxis studies. Briefly, each chemoattractant sample (600
μl) was loaded into the lower well, and 100 μl PBS without Ca2+ and Mg2+ containing 1 ×
105 fresh human blood neutrophils was added to the apical compartment of each transwell.
The plates were incubated for 60 min at 37°C in 5% CO2. Chemoattractants tested were sterile
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PBS without Ca2+ and Mg2+ (negative control) and WKYMVm. For inhibition studies,
neutrophils were pretreated with 10 μM WRW4 for 30 min at room temperature prior to use
in the chemotaxis assay. Following incubation, the supernatants from the upper and lower
compartments were removed, and a cytospin was performed. The upper surface of the polyester
membranes was wiped with cotton buds to remove nonmigrated cells, and the cells on the
underside of the membranes were fixed with methanol and stained with a Reastain Quick-Diff
(Reagena). The polyester membranes with migrated cells were removed with a curved, serrated
scalpel, and mounted “cell side up” on a microscope slide. The migrated cells were then counted
using a Zeiss light microscope at 1000× magnification. For each membrane, five fields of view
were counted, and results were expressed as a chemotactic index correct for migration observed
in the negative control.
Epithelial cell culture
Clonetics™ normal human bronchial epithelial (NHBE) cells were purchased from Cambrex
BioScience Ltd. (Wokingham, UK) and were cultured and maintained in bronchial epithelial
cell growth media (BEGM; Cambrex BioScience Ltd.), strictly in accordance with the
manufacturer's instructions. BEGM is a basal medium (Cambrex BioScience Ltd.)
supplemented with bronchial epithelial cell SingleQuots® growth factors and supplements
(Cambrex BioScience Ltd.) as a serum substitute optimized for growth, and appropriate
differentiation of these primary cells was used according to the manufacturer's instructions.
In situ cell death detection terminal deoxynucleotidyl transferase mediated deoxyuridine
triphosphate nick-end labeling (TUNEL) assay
Transwell® polyester-permeable supports (pore size 0.4 μm, diameter 6.5 mm; Corning Life
Sciences) were equilibrated for 45 min in BEGM before addition of 100 μl media containing
3.1 × 105 NHBE cells/ml into the apical compartment, with 600 μl medium in the basal
compartment. Cells were allowed to adhere overnight at 37°C, 5% CO2. The cells were exposed
in duplicate to LL-37 at the concentrations described or endotoxin-free water as a vehicle
control in fresh BEGM with the addition of 10% (v/v) heat-inactivated FBS in the apical and
basolateral compartments of all samples and incubated for 18–20 h at 37°C, 5% CO2. For
caspase inhibition studies, cells were exposed to 50 μM caspase inhibitor I (Z-VAD-FMK) for
4 h prior to LL-37 treatment. Cells were fixed in 10% neutral-buffered formalin (3.7%
formaldehyde) for 10 min, washed once in PBS, permeabilized in ice-cold 0.1% Triton
X-100/0.1% sodium citrate for 3 min, and then washed twice with PBS. An in situ cell death
detection kit (Roche Applied Science) was used according to the manufacturer's instructions.
The polyester membranes with cells were removed with a curved, serrated scalpel and mounted
cell side up on a microscope slide in 50 μl Vectashield® Hardset™ [containing 4′,6-
diamidino-2-phenylindole (DAPI)]. For each membrane, three random fields of view were
counted, each containing more than 100 cells, using an Axiovert S100 fluorescent microscope
and analyzed using OpenLAB 3.0 software. The level of apoptosis was expressed as the
percentage TUNEL-positive cells per DAPI-positive nuclei in the field of view.
Detection of cytokines
Fresh human blood neutrophils were plated at 4 × 105 cells in 400 μl RPMI-1640 media
[supplemented with 10% (v/v) heat-inactivated FBS, 1% (v/v) L-glutamine, 1 nM sodium
pyruvate], respectively, in 48-well plates. Cells were then incubated in media for 20 h in the
presence of P. aeruginosa H103 LPS, LL-37, cytokines (at the stated concentrations), or
endotoxin-free water as a vehicle control, in at least triplicate. Supernatants were collected and
stored at −20°C until use. The concentrations of TNF-α and IL-8 in the supernatants were
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measured using commercially prepared ELISA plates in accordance with the manufacturer's
instructions (BioSource International, Camarillo, CA).
Statistical analysis
Student's t-tests were performed to determine statistical significance, and P ≤ 0.05 was
considered significant. Values shown are expressed as mean ± SEM.
RESULTS
LL-37 inhibits neutrophil apoptosis
To evaluate the effect of LL-37 exposure on spontaneous neutrophil apoptosis, fresh human
peripheral blood neutrophils were isolated and incubated in culture over a range of LL-37
concentrations in the presence of 10% FBS. The level of apoptosis was assessed by FACS
quantification of FITC-labeled annexin V and propidium iodide staining. Confirmation of
apoptosis was obtained by morphological evaluation of cytospins, revealing the classical
appearance of cell shrinkage and nuclear condensation in apoptotic cells (Fig. 1A). In untreated
cells, spontaneous apoptosis was observed in 60.6% ± 3.6% (n=9) of cells at 20 h. Exposure
to LL-37 was demonstrated to inhibit neutrophil apoptosis significantly at 20 h (Fig. 1B). This
inhibition was dose-dependent, with significant inhibition (P=0.004) at LL-37 concentrations
of 250 ng/ml or greater, and profound inhibition of apoptosis observed at 10 μg/ml (diminished
by 86% of control levels; P=1×10−9) or above.
The consequence of LL-37-mediated inhibition of apoptosis in neutrophils at 20 h was
evaluated by FACS analysis, assessing the number of annexin V-negative/propidium iodide-
negative (viable) and annexin V-positive/propidium iodide-positive (necrotic) cells. In the
absence of LL-37, 26.2% ± 2.6% (n=9) of cells were viable, and 11.6% ± 1.5% (n=9) of cells
were necrotic at 20 h. Exposure to LL-37 resulted in dose-dependent increases in the
proportions of viable (Fig. 1C) and necrotic (Fig. 1D) cells. The proportion of viable cells
increased significantly after exposure to 100 ng/ml LL-37 (P=0.04) or greater and by up to
63% of control levels at 10 μg/ml. In contrast, the proportion of necrotic cells did not increase
significantly at concentrations of LL-37 below 1 μg/ml but was greatly increased by exposure
to higher levels of LL-37, by approximately fourfold of control levels at 10 μg/ml.
To confirm that exposure to LL-37 did not induce early neutrophil cytolysis, cells were also
examined over a time course using FACS analyses and total cell counts. Negligible levels of
apoptosis and necrosis were observed by FACS at 0 h (data not shown), 1 h (Fig. 2A), and 4
h (Fig. 2B), but inhibition of apoptosis by LL-37 was confirmed at 20 h, with resultant increases
in the numbers of viable and necrotic cells observed (Fig. 2C), as described. In addition, total
cell counts were performed by haemocytometer (Fig. 2D) to examine the possibility that
cytolytic destruction could remove cells from FACS and cytological analyses. No significant
loss of cells was observed at 0, 1, or 4 h after exposure to LL-37 at any concentration tested or
at 20 h at ≤10 μg/ml LL-37. However, a significant decrease (P=0.02) in total cell number was
observed only after 20 h exposure to quite high concentrations of LL-37 (25 μg/ml).
Consequently, as a proportion of the initial cell population, FACS and cytospin-based analyses
could have modestly underestimated the degree of LL-37-mediated inhibition of apoptosis and
the increase in necrosis, induced by the most extreme conditions examined (20 h exposure to
25 μg/ml of LL-37).
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LL-37 exposure modulates expression of Mcl-1 and inhibits cleavage of BID and
procaspase-3 in neutrophils
To study the mechanisms by which LL-37 can modulate the apoptosis of neutrophils, the
expression of critical apoptosis-regulating Bcl-2 family proteins and the cleavage of
procaspase-3 were examined by Western immunoblot. Fresh human peripheral blood
neutrophils were examined at 4 h after exposure to LL-37 in the presence of 10% FBS, a time-
point chosen to precede any substantial apoptosis or necrosis with 94–96% cell viability
observed, irrespective of exposure to LL-37 (Fig. 2B). Expression of the antiapoptotic protein
Mcl-1 is of particular importance in neutrophils [29] and was found to be significantly higher
in neutrophils after 4 h exposure to LL-37 (Fig. 3A) with dose-dependent regulation. Cleavage
of the “BH3 domain only” Bcl-2 protein BID by caspase-8 generates a proapoptotic fragment
[30,31] and was demonstrated to be inhibited significantly in neutrophils exposed to LL-37
(Fig. 3B). In addition, significantly higher levels of the inactive procaspase-3 protein, with a
corresponding, significant decrease in levels of active-cleaved caspase-3, were observed after
exposure to LL-37 (Fig. 4, A and B), indicating inhibition of the activation pathways for the
effector caspase-3 and correlating with LL-37-mediated inhibition of neutrophil apoptosis.
LL-37-induced inhibition of neutrophil apoptosis involves multiple signaling pathways
The immunomodulatory effects of LL-37 have been proposed to be dependent on signaling
through a number of receptors, potentially relevant in this system, including the G-protein-
coupled receptor FPRL-1 [19] and the purinergic receptor P2X7 [32]. Additional, as-yet-
unidentified G-protein-coupled receptors and undetermined high- and low-affinity receptors
have also been proposed [33-35]. To assess the possible significance of these receptors, human
peripheral blood neutrophils were preincubated with PTX (to inhibit G-protein-coupled
receptors), WRW4, or oxidized ATP (specific inhibitors of FPRL-1 [36] and P2X7 [32]
receptors, respectively) before exposure to a concentration range of LL-37 in the presence of
10% FBS. The levels of spontaneous apoptosis were subsequently determined after 20 h
incubation (Fig. 5A). No significant LL-37-mediated inhibition of neutrophil apoptosis
occurred in the presence of oxidized ATP or PTX at concentrations of LL-37 up to 1 μg/ml,
demonstrating effective blockade of LL-37 activity. In contrast, WRW4, at the optimal
concentration for near-complete inhibition of the FPRL-1-specific agonist WKYMVm [36],
did not impair the activity of LL-37, and significant LL-37-mediated inhibition of neutrophil
apoptosis was observed at 250 ng/ml (P=0.009) and 1 μg/ml LL-37 (P=0.01) in the presence
of WRW4. To further evaluate the role of FPRL-1 in this system, human peripheral blood
neutrophils were incubated with the FPRL-1-specific agonist WKYMVm at 0.2 μM and 10
μM (approximately equimolar with 1 μg/ml and 50 μg/ml LL-37, respectively). No significant
effects of this agonist were observed on the level of spontaneous apoptosis after 20 h incubation
(Fig. 5B). To confirm the biological activity of our WKYMVm and WRW4 peptides,
chemotaxis of fresh human neutrophils was studied. As described previously [37], significant
chemotaxis of neutrophils was observed in response to 10 μM WKYMVm (P=0.001). This
chemotaxis was inhibited significantly by preincubation with 10 μM WRW4 (P=0.02; Fig.
5C). These data suggest that P2X7 receptors and an undetermined G-protein-coupled receptor
other than FPRL-1 are required for LL-37-mediated inhibition of neutrophil apoptosis.
LL-37 has also been demonstrated to induce MAPK activation in a cell type-specific manner,
through a PTX-insensitive pathway [22,38], and to enhance the GM-CSF-dependent activation
of these pathways in primary monocytes [38]. GM-CSF is a potent inhibitor of neutrophil
apoptosis, with this effect mediated through the activation of ERK1/2 MAPK and PI-3K
pathways [39]. Thus, to determine the significance of these pathways in this system, human
peripheral blood neutrophils were preincubated with PD098059 (inhibitor of the ERK1/2
MAPK pathway via MAPK kinase) or wortmannin (PI-3K inhibitor) before exposure to a dose
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range of LL-37. The levels of spontaneous apoptosis were subsequently determined after 20 h
incubation (Fig. 5A). The inhibition of the ERK1/2 MAPK pathway alone resulted in a degree
of inhibition of neutrophil apoptosis but did not impair the effects of LL-37, and significant
LL-37-mediated inhibition of neutrophil apoptosis was observed at 250 ng/ml (P=0.0005) and
1 μg/ml LL-37 (P=0.005) in the presence of PD098059. In contrast, although some inhibition
of LL-37 was observed in the presence of wortmannin, concentrations of LL-37 up to 1 μg/ml
were unable to inhibit neutrophil apoptosis significantly in the presence of this PI-3K blockade.
To confirm the biological activity of our PD098059, GM-CSF-mediated inhibition of
neutrophil apoptosis was demonstrated to be blocked significantly by preincubation with 10
μM or 50 μM PD098059 (P=0.002 and P=0.006, respectively; Fig. 5D), as described previously
[39]. These data suggest that LL-37 may use the PI-3K but not the ERK1/2 MAPK pathway
in the inhibition of neutrophil apoptosis.
LL-37 differentially modulates neutrophil cytokine responses to inflammatory stimuli
To evaluate the function of primary human neutrophils prevented from undergoing
spontaneous apoptosis by exposure to LL-37, cytokine responses to inflammatory stimuli were
examined. Neutrophils were incubated for 20 h with LPS, IL-1β, or TNF-α in the presence of
10 μg/ml LL-37 (the optimal concentration for the inhibition of apoptosis in the absence of
cytolytic cell loss at this time-point) and 10% FBS, with subsequent determination of the
cytokine responses by ELISA analysis of cell supernatants (Fig. 6, A and B). As expected, on
the basis of the well-characterized, anti-endotoxic effects ascribed to this peptide in the
responses of other cell types, LL-37 inhibited the release of IL-8 and TNF-α in response to
LPS exposure. However, in contrast, LL-37 exposure of neutrophils enhanced significantly,
but modestly, the release of IL-8 and TNF-α (P=0.04 and P=0.01, respectively) in response to
stimulation with IL-1β and mediated a trend toward enhanced IL-8 production in response to
TNF-α (with significant up-regulation in two out of four donors; P<0.01). These data
demonstrate functional cytokine responses in LL-37-treated neutrophils and indicate that
LL-37 modulates the cytokine responses of neutrophils to inflammatory signals in a stimulus-
specific manner.
LL-37 induces apoptosis in primary airway epithelial cells
In contrast to the potent LL-37-mediated inhibition of apoptosis observed in neutrophils, we
have recently described the capacity of LL-37 to mediate a dose-dependent induction of
apoptosis in immortalized airway epithelial cells lines [40]. Incubation with 25 μg/ml LL-37
or higher concentrations induced a human serum-sensitive induction of TUNEL positivity and
cleavage of caspase-3 (to the active form) in A549 human lung epithelial cells and 16HBE4o-
human airway epithelial cells [40]. To confirm the significance of these observations in
nonimmortalized cells, the effect of LL-37 on primary human bronchial epithelial cells cultured
on semipermeable growth support membranes was evaluated in parallel with the freshly
isolated human neutrophils described above, incubated for 20 h over a concentration range of
LL-37 or vehicle-alone control, all in the presence of 10% FBS (Fig. 7A). Analysis
demonstrated a significant LL-37-mediated increase in TUNEL-positive cells, suggestive of
caspase-activated DNase activity during apoptosis upon exposure to 10 μg/ml LL-37 (P=0.003)
and above, and up to 55% of cells were TUNEL-positive after exposure to 100 μg/ml LL-37.
Preincubation with a caspase inhibitor blocked the proapoptotic effects of exposure to 25 μg/
ml and 50 μg/ml LL-37. This was statistically significant at 50 μg/ml LL-37 (where a greater
induction of apoptosis was observed; P=0.05) but despite being consistently inhibitory, failed
to reach statistical significance at 25 μg/ml LL-37 (where variation in the lower absolute level
of induction of apoptosis was observed; P=0.08). These data are indicative of caspase-
dependent, programmed cell death in these LL-37-treated primary airway epithelial cells,
although the possibility of an additional, contributory caspase-independent apoptosis, as
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described previously in a carcinoma cell line exposed to an LL-37 derivative [41], cannot be
excluded.
DISCUSSION
Various cationic host-defense peptides [including LL-37 and the murine homologue
cathelicidin-related antimicrobial peptide (mCRAMP)] have been demonstrated recently to
have multiple immunomodulatory capabilities, potentially representing key mechanisms by
which these peptides can enhance host clearance of infection in vivo. The full extent of these
immunomodulatory functions and the precise mechanisms by which these peptides contribute
to innate immunity remain undetermined in vivo and are of clear significance in the
development of such peptides and their synthetic analogs as novel, antimicrobial therapeutics
for multiple antibiotic-resistant infections.
The microbicidal activity of LL-37 is acutely sensitive to serum proteins and largely inhibitable
under physiologically relevant, ionic conditions [42], although other recently proposed
cleavage forms of hCAP-18 may have more effective microbicidal activities [43,44]. However,
various immunomodulatory properties have been demonstrated in physiological ionic
environments, including leukocyte chemotaxis, stimulation of epithelial cell IL-8 production,
post-translational modification of IL-1β, modulation of macrophage transcription,
angiogenesis, enhanced wound-healing, modulation of dendritic cell differentiation and
function, and adjuvant properties [12,14,19-22,32,34,35,45-48]. Demonstrating the relative
contribution of direct microbicidal activity versus antimicrobial immunomodulatory functions
in vivo remains challenging. Studies of mCRAMP indicate that despite high minimum
inhibitory concentration values (even against a susceptible mutant bacteria), direct
microbicidal activity may contribute to host defense in vivo in specific systems, perhaps at
higher concentrations under favorable conditions in a protected niche or functioning
synergistically [49,50]. However, we have recently described in vivo protection against
infection in animal models using a synthetic CHDP derivative with no direct in vitro
antimicrobial activity [42]. Thus, the multiple immunomodulatory properties described for
LL-37 in vitro and in vivo seem likely to be fundamental to the importance of this peptide to
the innate immune system.
The precise mechanisms underlying the immunomodulatory effects of LL-37 are in many cases
unknown. A number of identified and undefined receptors have been described for LL-37,
including FPRL-1 and other G-protein-coupled receptors, epidermal growth factor receptor
(EGFR), responsive via metalloproteinase-mediated cleavage of membrane-anchored EGFR
ligands, and P2X7 receptors acting via caspase-1 [19,22,32-35,38]. However, the relative
significance of these receptors remains unclear, and traditional, ligand-binding receptor
mechanisms may not fully determine peptide activities [44]. In addition, MAPK activation is
involved in G-protein-independent LL-37 stimulation of monocytes [38], and endocytic
peptide uptake in airway epithelial cells in vitro is required for LL-37-induced IL-8 expression
[33,42].
We demonstrate that in addition to the immunomodulatory functions of LL-37 described
previously, this CHDP is capable of modulating apoptotic pathways in primary human innate-
immune effector cells. The capacity of LL-37 to act as a potent inhibitor of spontaneous
neutrophil apoptosis was demonstrated to involve signaling via P2X7 receptors and G-protein-
coupled receptors other than FPRL-1. These data confirm and complement some of the
observations made in a recent related paper [51]. However, in contrast to our observations,
Nagaoka et al. [51] observed a role for FPRL-1 in LL-37-mediated inhibition of neutrophil
apoptosis. The reasons for this difference remain to be determined but may relate to alternate
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sources of FPRL-1 antagonistic and agonistic peptides (subjected to functional validation by
reproducing well-characterized activities of these peptides in other systems in our study),
different peptide solvents, or technical differences in neutrophil purification, which might
result in differential background levels of contaminant cell types with FPRL-1-mediated
responses to LL-37, which could influence the response of neutrophils in these assays.
Nevertheless, the observation that a combination of receptor types could be involved in LL-37
signaling was also the conclusion of a recent study examining the effects of LL-37 on
keratinocyte functions [44]. That study, interestingly, also demonstrated similar responses
when using D-LL-37 (composed of amino acids in the synthetic D form), arguing against a
highly structure-specific interaction between LL-37 and cell surface receptors. Thus, we cannot
exclude a complexity exceeding the use of P2X7 receptors and G-protein-coupled receptors in
LL-37-mediated inhibition of neutrophil apoptosis. Regardless, our data suggest that this
process involves subsequent downstream activation of PI-3K but not the ERK1/2 MAPK
pathway. The latter observation is in keeping with the recent demonstration that in contrast to
its effects in monocytes and epithelial cells [22,38], LL-37 does not stimulate ERK1/2
phosphorylation in neutrophils [20].
We also demonstrate that LL-37 mediates antiapoptotic effects in neutrophils via an inhibitory
effect on the activation of the effector caspase-3 and by altering the balance of Bcl-2 family
proteins. It is interesting to note that these effects, observed after 4 h of incubation with LL-37,
preceded substantial membrane translocation of phosphatidylserine (PS), assessed by FACS
analyses of FITC annexin V/propidium iodide-stained cells. Although translocation of PS was
not observed in substantial numbers of neutrophils at 4 h, compared with later time-points,
there was an increase in FITC-annexin V-positive/propidium iodide-negative cells from ∼1%
at 1 h to ∼4% at 4 h in control cells (Fig. 2, A and B). After this time-point, apoptosis determined
by translocation of PS increased rapidly, and ∼15% of control neutrophils were FITC-annexin
V-positive/propidium iodide-negative at 6 h (data not shown), demonstrating the temporal
sequence of events in apoptosis of these cells. These data support previous studies indicating
that the translocation of PS is a caspase-3-dependent event downstream of caspase activation
[52] and that LL-37-mediated inhibition of caspase-3 cleavage precedes effects on
translocation of PS in neutrophils undergoing spontaneous apoptosis.
LL-37 modulated expression of the anti-inflammatory protein Mcl-1, preventing the loss of
expression associated with spontaneous apoptosis. This Bcl-2 family protein has a short half-
life, providing rapid response to environmental stimuli and playing a critical role in promoting
neutrophil survival by inhibiting mitochondrial damage and cytochrome c release [29,53].
LL-37 also inhibited cleavage of the BH3 domain-only Bcl-2 protein BID, therefore decreasing
generation of the proapoptotic p15 BID cleavage fragment, believed to translocate to the
mitochondria and trigger release of cytochrome c during the induction of apoptosis [30,31].
Cleavage of BID by caspase-8 is critical for death receptor-induced apoptosis but also plays
an important role in spontaneous neutrophil apoptosis, even in the absence of death receptor
stimulation [54]. In addition to the inhibition of cleavage of the key effector caspase-3, these
observations suggest that LL-37 exerts its antiapoptotic effect on neutrophils by acting
upstream of mitochondria on intrinsic and traditionally extrinsic pathways for the induction of
programmed cell death.
The consequences for LL-37-mediated inhibition of neutrophil apoptosis in vitro were
demonstrated to be dependent on the concentration of LL-37. After 20 h exposure to lower
concentrations of LL-37, significant increases were observed in the proportion of viable cells
at the expense of apoptotic cells. However, at higher concentrations of LL-37, despite further
increases in the proportion of viable cells, the more dramatic decreases in apoptotic cells were
accompanied by an increase in neutrophil necrosis. This switch in cellular fate, evident at
approximately 10 μg/ml, could represent a transition to inflammatory concentrations of LL-37
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in vivo [4]. The neutrophil necrosis observed is likely a consequence of the inhibition of
apoptotic pathways, rather than secondary necrosis of apoptotic cells, given the potent
inhibition of apoptotic pathways observed after 4 h exposure to LL-37, before any substantial,
detectable cell death, and bears similarities to the recently reported effects of LPS in inhibiting
apoptosis but inducing necrosis in neutrophils [55]. In contrast, the antiapoptotic factor GM-
CSF acts primarily as a potent neutrophil-survival factor [56]. Thus, although LL-37-mediated
inhibition of apoptosis led to a dose-dependent increase in neutrophil survival, higher
concentrations of peptide also promoted an additional switch from apoptotic to necrotic cell
death.
The in vivo consequences of LL-37-mediated inhibition of neutrophil apoptosis remain to be
determined. Low-level, acute increases in LL-37 may primarily enhance neutrophil survival,
promoting the clearance of infection. However, although necrosis induced by higher
concentrations of LL-37 could be beneficial to the host by amplifying the acute inflammatory
response (as proposed previously for LPS-induced necrosis [55]), the uncontrolled release of
neutrophil contents in chronic inflammation would be expected to result in host damage and
impair the resolution of inflammation. In addition to enhancing neutrophil survival, LL-37 has
previously been demonstrated to be chemotactic for neutrophils in vitro, directly [19] and
indirectly, by inducing IL-8 production by epithelial cells [12], and the murine homologue
CRAMP has been shown to induce neutrophil recruitment in vivo in a mouse model [21].
Further, LL-37 release by recruited neutrophils would therefore amplify these responses and
the effects of LL-37 on neutrophil apoptosis.
We demonstrate that neutrophils undergoing LL-37-mediated inhibition of apoptosis continued
to respond to inflammatory stimuli, indicating continued functional competence. Furthermore,
we show that in contrast to the inhibition of LPS-induced cytokine production (as observed
previously in vivo [12,15] and in other cell types in vitro [12,45,57]), LL-37 failed to inhibit
and indeed, slightly enhanced the cytokine response of neutrophils to IL-1β or TNF-α. These
data confirm our recent observations, suggesting that LL-37 is not anti-inflammatory per se
[45] but might differentially modulate responses to endogenous host inflammatory signals as
compared with exogenous pathogen-derived molecular patterns. It is interesting that LL-37
has also previously been shown to promote IL-1β processing and release by LPS-primed
monocytes [32]. We have demonstrated that LL-37 has direct effects on the proinflammatory
and anti-inflammatory properties of mammalian cells [12] and inhibited LPS-induced,
proinflammatory cytokine expression, in part by acting directly on the Toll-like receptor to
nuclear factor-κB pathway [45]. However, the potent effects of LL-37 on LPS-induced
responses also likely reflect the ability of LL-37 to bind LPS [58], inhibit LPS-binding protein
interaction [59], and effectively neutralize the LPS. The mechanisms responsible for the modest
but significant increases in cytokine production by LL-37-treated neutrophils following
exposure to IL-1β or TNF-α remain undetermined but could simply reflect the increased
numbers of viable neutrophils in the LL-37-treated population as a consequence of LL-37-
mediated inhibition of apoptosis.
In contrast to the LL-37-mediated inhibition of apoptosis observed in neutrophils, we
demonstrate that LL-37 induced caspase-dependent cell death in primary airway epithelial
cells. These data are compatible with our recent observation of LL-37-induced apoptosis in
immortalized epithelial cell lines [40] but demonstrate an increased sensitivity of these primary
cells to lower doses of LL-37. In addition, these data contrast with the effects demonstrated in
neutrophils, suggesting the induction of apoptosis in primary airway epithelial cells in response
to concentrations of LL-37, which mediated inhibition of apoptosis in neutrophils at the same
time-point and under identical serum conditions. The underlying mechanisms that result in
these strikingly divergent consequences for LL-37-mediated modulation of apoptotic pathways
in different human primary innate-immune effector cells remain unclear. However, it is
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interesting to note that although our data implicate P2X7 receptors in LL-37-mediated
inhibition of apoptosis in neutrophils, the induction of apoptosis has been described in human
cervical epithelial cells following activation of these receptors with ATP, mediated
predominantly by the caspase-9 (instrinsic mitochondrial) pathway [60]. Indeed P2X7 receptor
activation has recently been proposed to be capable of inducing a state of initially reversible
“pseudoapoptosis” in the human embryonic kidney 293 epithelial cell line, which can proceed
to apoptotic and/or necrotic cell death dependent on the length of receptor activation [61]. This
raises the possibility of a common receptor use in different cell types but resulting in the
initiation of contrasting downstream signaling effects in epithelial cells as compared with
neutrophils. Future assessment and comparison of these processes are expected to be instructive
in dissecting the mechanisms underlying these contrasting immunomodulatory activities of
LL-37.
In addition, the consequences of LL-37-induced epithelial cell apoptosis in the context of an
infectious insult remain to be determined. This response could be detrimental to the host if
excessive cell death results in a breach of epithelial integrity. However, apoptosis of infected
epithelial cells has been proposed as an innate defense mechanism for clearance of P.
aeruginosa by airway epithelium [62,63] and a defense against Escherichia coli infection in
the bladder epithelium [64]. In this context, LL-37-induced apoptosis could represent an innate
host defense response, complemented by an LL-37-induced enhancement of wound-healing
for resolution of inflammation [14,46,47]
Thus, raised levels of LL-37 in an acute inflammatory scenario could contribute to innate host
defenses by mediating recruitment and enhanced survival of neutrophils, apoptosis of infected
epithelial cells, and the modulation of innate immune cell responses to endogenous
inflammatory signals to enhance the resolution of an acute, infectious insult. A full knowledge
of the in vivo significance of these LL-37-mediated immunomodulatory activities and their
applicability to other CHDP is essential in developing the potential of CHDP as future
immunomodulatory, antimicrobial therapeutics.
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Fig 1.
Inhibition of neutrophil apoptosis by LL-37. Neutrophils were incubated for 20 h over a range
of LL-37 concentrations in the presence of 10% FBS. Modulation of spontaneous apoptosis
was examined by FACS analysis and morphology. (A) Representative fields from cytospins.
White arrows indicate examples of apoptotic neutrophils, 320× original magnification. (B–D)
FACS analysis was used to determine the percentage of neutrophils, which were (B) apoptotic
(FITC-annexin V-positive, propidium iodide-negative), (C) viable (FITC-annexin V-negative,
propidium iodide-negative), and (D) necrotic (FITC-annexin V-positive, propidium iodide-
positive). Figures represent the percentage of cells in LL-37-treated samples as a proportion
of that observed in the vehicle alone-treated controls to correct for donor variation and indicate
mean values ± SEM, for n ≥ 6 for each condition, performed in duplicate, using seven different
donors. Significance was assessed using absolute values in LL-37-treated samples compared
with vehicle alone-treated controls by paired sample t-test analyses. *, P ≤ 0.05; **, P ≤ 0.01.
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Fig 2.
LL-37-mediated inhibition of neutrophil apoptosis occurs in the absence of cytolysis.
Neutrophils were incubated over a range of LL-37 concentrations in the presence of 10% FBS
for 0, 1, 4, or 20 h. (A–C) FACS analysis was used to determine the percentage of neutrophils
that were apoptotic (FITC-annexin V-positive, propidium iodide-negative), viable (FITC-
annexin V-negative, propidium iodide-negative), and necrotic (FITC-annexin V-positive,
propidium iodide-positive) at (A) 1 h, (B) 4 h, and (C) 20 h. (D) Total cell counts were
performed in duplicate using a haemocytometer and represented as a proportion of the number
of cells in the vehicle-alone controls at each time-point. No significant difference was observed
between control samples over the time course. Figures indicate mean values ± SEM for n = 4 for
each condition using four different donors. Significance was assessed using absolute values in
LL-37-treated samples compared with vehicle alone-treated controls by paired sample t-test
analyses. *, P ≤ 0.05; **, P ≤ 0.01.
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Fig 3.
Modulation of neutrophil Mcl-1 expression and cleavage of BID in response to LL-37.
Neutrophils were exposed to a concentration range of 0.25–50 μg/ml LL-37, 30 ng/ml GM-
CSF as a positive control, or endotoxin-free water as a vehicle control for 4 h in the presence
of 10% FBS. Whole cell protein lysates were prepared and analyzed by SDS-PAGE and
Western immunoblotting. Immunoblots for expression of (A) Mcl-1 and (B) uncleaved BID
are shown, each representative of n = 3 different donors, and expression of the housekeeping
protein GAPDH was assessed as a loading control. Quantitative densitometry was performed,
corrected for protein loading, expressed as a proportion of the vehicle alone-treated control
sample, and displayed as mean values ± SEM for n = 3 different donors. t-Test analyses were
used to compare Mcl-1 or BID expression in LL-37- or GM-CSF-exposed samples with vehicle
alone-treated controls. *, P ≤ 0.05.
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Fig 4.
Modulation of procaspase-3 cleavage in LL-37-treated neutrophils, which were exposed to a
concentration range of 0.25–50 μg/ml LL-37, 30 ng/ml GM-CSF as a positive control, or
endotoxin-free water as a vehicle control for 4 h in the presence of 10% FBS. Whole cell protein
lysates were prepared and analyzed by SDS-PAGE and Western immunoblotting. (A)
Immunoblots for expression of inactive procaspase-3 and active-cleaved caspase-3 are shown,
representative of n = 5 different donors, and expression of the housekeeping protein GAPDH
was assessed as a loading control. (B) Quantitative densitometry was performed, corrected for
protein loading, expressed as a proportion of the vehicle alone-treated control sample, and
displayed as mean values ± SEM for n = 5 different donors. t-Test analyses were used to compare
procaspase-3 and cleaved caspase-3 expression in LL-37- or GM-CSF-exposed samples with
vehicle alone-treated controls. *, P ≤ 0.05; **, P ≤ 0.01.
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Fig 5.
LL-37-induced inhibition of neutrophil apoptosis involves multiple signaling pathways.
Neutrophil apoptosis over 20 h incubation was examined in duplicate by FACS analysis for
FITC-annexin V-positive, propidium iodide-negative cells after (A) incubation with 0.25 μg/
ml or 1 μg/ml LL-37 or endotoxin-free water as a vehicle control, added 30 min after 100 μM-
oxidized ATP, 10 μM WRW4, 200 ng/ml PTX, 50 μM PD098059, 5 μM wortmannin, or a
vehicle-alone control in the presence of 10% FBS. Results represent the percentage of apoptotic
cells as mean ± SEM for n ≥ 4 per condition from five different donors. Paired sample t-test
analyses were used to compare LL-37-treated samples with controls under the same inhibitor
conditions. **, P ≤ 0.01, or (B) incubation with 1 μg/ml LL-37, 0.2 μM or 10 μM WKYMVm,
or a vehicle-alone control. Results represent the percentage of apoptotic cells as mean ± SEM for
n = 3 from three different donors. Paired sample t-test analyses were used to compare treated
samples with controls. **, P ≤ 0.01. (C) Neutrophil chemotaxis was assessed in triplicate in
response to 10 μM WKYMVm or vehicle-alone control after preincubation with 10 μM WRW4
or vehicle-alone control, and the chemotactic index was displayed as mean ± SEM for n = 3 from
three different donors. Paired sample t-test analyses were used to compare WKYMVm-treated
samples with controls and WRW4-pretreated samples with WKYMVm alone. *, P ≤ 0.05; **,
P ≤ 0.01. (D) Neutrophil apoptosis over 20 h incubation was examined in duplicate by FACS
analysis after incubation with 20 μg/ml GM-CSF or endotoxin-free water as a vehicle control,
added 30 min after 10 μM or 50 μM PD098059 or vehicle-alone control. Results represent the
percentage of apoptotic cells as mean ± SEM for n = 3 per condition from three different donors.
Paired sample t-test analyses were used to compare GM-CSF-treated samples with controls
and PD098059-pretreated samples with GM-CSF alone. *, P ≤ 0.05; **, P ≤ 0.01.
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Fig 6.
Modulation of neutrophil cytokine responses by LL-37. The IL-8 or TNF-α production by
neutrophils was assessed by ELISA analysis of culture supernatants following incubation of
cells for 20 h in the presence of (A) 100 ng/ml LPS, 10 ng/ml IL-1β, 100 ng/ml TNF-α, or
vehicle-alone control, with 10 μg/ml LL-37 or vehicle-alone control in the presence of 10%
FBS; or (B) 100 ng/ml LPS, 50 ng/ml IL-1β, or vehicle-alone control with 10 μg/ml LL-37 or
vehicle-alone control in the presence of 10% FBS. Data represent means ± SEM for n ≥ 3 replicates
per condition from four different donors. Paired sample t-test analyses were used to compare
LL-37-treated samples with controls under the same stimulatory conditions. *, P ≤ 0.05; **,
P ≤ 0.01.
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Fig 7.
Induction of caspase-dependent cell death in primary bronchial epithelial cells by LL-37.
Primary human bronchial epithelial cells were exposed to (A) a concentration range of 1–100
μg/ml LL-37 or endotoxin-free water as a vehicle control, all in the presence of 10% FBS for
20 h or (B) pretreated with 50 μM caspase inhibitor I (Z-VAD-FMK) for 4 h prior to the addition
of 25 μg/ml or 50 μg/ml LL-37 in the presence of 10% FBS for 20 h. Cells were fixed, and
apoptosis was assessed by TUNEL assay. Three random fields of view, each containing more
than 100 cells, were counted for each sample, and the percentage of TUNEL-positive cells in
the field of view was expressed as a percentage of the number of DAPI-positive nuclei. Data
represent means ± SEM for n = 6 (A) or n = 3 (B). t-Test analyses were used to compare LL-37-
treated samples with controls. *, P ≤ 0.05; **, P ≤ 0.01.
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